Postoperative Cognitive Dysfunction in Patients Undergoing Pituitary Removal Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Cennet Tor Kılıç
- Phone Number: +903038248
- Email: cennetmfk34@gmail.com
Study Locations
-
-
-
Kocaeli, Turkey, 41350
- Recruiting
- Kocaeli University
-
Contact:
- Cennet Tor Kılıç
- Phone Number: +902623038473
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ASA I-II patients
- Undergoing elective pituitery tumor removal surgery
Exclusion Criteria:
- >II ASA scores
- Using antidepressant agents
- Patient refusal
- Mental diseases
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group1
patients undergoing pituitary tumor removal surgery will be tested with standardized minimental testing.
|
To diagnose postoperative cognitive dysfunction
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
minimental test score
Time Frame: preoperative 24th hour
|
scores between 0-30
|
preoperative 24th hour
|
|
minimental test score
Time Frame: postoperative 4th hour
|
scores between 0-30
|
postoperative 4th hour
|
|
minimental test score
Time Frame: postoperative 24th hour
|
scores between 0-30
|
postoperative 24th hour
|
|
minimental test score
Time Frame: one month after discharged
|
scores between 0-30
|
one month after discharged
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Cennet Tor Kılıç, Kocaeli University
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Postoperative Complications
- Neurocognitive Disorders
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Hypothalamic Diseases
- Hypothalamic Neoplasms
- Supratentorial Neoplasms
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Cognition Disorders
- Pituitary Neoplasms
- Pituitary Diseases
- Cognitive Dysfunction
- Postoperative Cognitive Complications
Other Study ID Numbers
Other Study ID Numbers
- GOKAEK 2017/153
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.